



RECEIVED

MAY 25 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6
gns

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

Ariel Fletcher

5/17/2001
Date of Deposit

Applicant: Webb, et al.)
Serial No.: 09/715,891) Art Unit: 1644
Filed: November 17, 2000) Examiner: F.P. VanderVegt
For: MHC CLASS II ANTIGEN PRESENTING)
SYSTEMS AND METHODS FOR)
ACTIVATING CD4⁺ CELLS) Our Ref.: TSRI 536.1 D2
)

RESPONSE TO NOTICE TO COMPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the enclosed Notice to Comply mailed March 20, 2001 in connection with the above-identified application. The response is accompanied by a petition for a one month extension of time and the requisite fee, thus making the present response a timely filing.

The Sequence Listing in the present application 09/715,891 is identical with that filed on May 22, 1997 in PCT Application Serial No. PCT/US97/08697, having a filing date of May 22, 1997. In accordance with 37 CFR 1.821(e), please use the computer readable form filed on May 22, 1997 in PCT Application Serial No. PCT/US97/08697 as the computer readable form for the instant application. It is understood that the Patent and Trademark

- 2 -

Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing, identical to that in PCT Application Serial No. PCT/US97/08697, is submitted herewith.

The undersigned hereby states that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821-1.825 are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

If any additional fees, other than the extension of time fee submitted herewith, are associated with this Response are required, please charge our Deposit Account No. 19-0962.

Respectfully submitted,

By Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937
LL\c:\WP\SEQ\SCR2289P.resNTC

RECEIVED

MAY 25 2001

TECH CENTER 1600/2900

Application No.: ~~09/71587~~

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE